Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma
This study is currently recruiting participants.
Verified March 2013
by City of Hope Medical Center
Study NCT00577278 Information provided by City of Hope Medical Center
First Received on December 19, 2007. Last Updated on March 6, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Graft Versus Host Disease
Leukemia
Lymphoma
Additional conditions recognized in this trial
Graft vs Host Disease
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
rituximab
fludarabine phosphate
melphalan
sirolimus
tacrolimus
indium In 111 ibritumomab tiuxetan
yttrium Y 90 ibritumomab tiuxetan
Additional drug interventions recognized in this trial
Antibodies, Monoclonal
Everolimus
Fludarabine
Fludarabine monophosphate
Vidarabine
More general drug interventions related to this trial
Alkylating Agents
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antirheumatic Agents
Antiviral Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
City of Hope Medical Center
National Cancer Institute (NCI)
Back to top of Main Content
